skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Executive Summary 

In the United States (U.S.), approximately 85.6 million adults have at least one type of cardiovascular disease (CVD), a broad group of disorders that affect the heart and circulatory system. Cardiovascular disease in all its forms accounts for more deaths than any other major cause in the U.S., including cancer, with one of every three deaths in the country due to CVD and over 2,200 people dying from the disease each day (or an average of one death from CVD every 40 seconds).

Coronary heart disease (CHD), also known as ischemic heart disease, is a form of CVD that is associated with a reduction in blood flow through the vasculature of the heart. Classified under the umbrella of CHD are acute and chronic conditions such as atherosclerosis, angina pectoris, and myocardial infarction (MI). Approximately 15.5 million adults age 20 or older in the U.S. suffer from CHD, which is the single largest cause of death in the U.S. and also is the greatest cause of premature and permanent disability in the labor force (AHA, 2016).

 

 

U.S. Markets for Interventional Cardiology Products

This report will cover: interventional diagnostic and therapeutic products for the treatment of CVD; procedure and market forecasts for the years 2015 to 2020 key market drivers and limiters; estimated revenues and market shares for major U.S. competitors; and, analysis of lead products and emerging products/technologies.
U.S. Markets for Interventional Cardiology Products Meddevicetracker

Read also

  • Biomedtracker: follow the drug development process

    Biomedtracker 2018 Early Outlook Report

    What's on the horizon for pharma in 2018? Find out with Biomedtracker&rsquo;s Early 2018 Outlook Report extract. Download free extracts from this essential report, which investigates the catalysts expected to occur in the first part of the year for 21 different drugs.<br />

    Topics Drug development landscape

  • Biomedtracker: follow the drug development process

    Accurate, Intuitive and Updated In Real Time

    03 Apr 2017

    Learn why pharmaceutical, biotech, and investment companies rely on BioMedTracker for its insight on the likelihood of approval, commercial potential, and future data and regulatory catalysts for drugs within the competitive landscape of every important disease and indication.

  • In Vivo: strategic insights for life sciences decision-maker...

    Pharma News and Healthcare Business Insights

    <p><span>Pharma Intelligence offers a wealth of pharmaceutical industry news and strategic insight into the healthcare &amp; biotechnology markets from around the world. Working in an interconnected global network, our 65 journalists and over 300 in-house analysts supply comprehensive analysis and reports.</span></p>

;

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: